Lynch & Associates Eli Lilly & CO Transaction History

Lynch & Associates

$440 Million
Q2 2024

A detailed history of Lynch & Associates transactions in Eli Lilly & CO stock. As of the latest transaction made, Lynch & Associates holds 7,721 shares of LLY stock, worth $6.88 Million. This represents 1.59% of its overall portfolio holdings.

Number of Shares

7,721

Previous 7,721 -0.0%

Holding current value

$6.88 Million

Previous $6.01 Million 16.38%

% of portfolio

1.59%

Previous 1.4%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	BUY	$592.2 - $792.28 $84,684 - $113,296	143 Added 1.89%	7,721 $6.01 Million
Q4 2023 Jan 08, 2024	SELL	$525.19 - $619.13 $55,670 - $65,627	-106 Reduced 1.38%	7,578 $4.42 Million
Q3 2023 Oct 24, 2023	SELL	$434.7 - $599.3 $10,867 - $14,982	-25 Reduced 0.32%	7,684 $4.13 Million
Q2 2023 Oct 24, 2023	SELL	$350.74 - $468.98 $122,057 - $163,205	-348 Reduced 4.32%	7,709 $3.62 Million
Q2 2023 Jul 13, 2023	SELL	$350.74 - $468.98 $122,057 - $163,205	-348 Reduced 4.32%	7,709 $3.62 Million
Q1 2023 Oct 24, 2023	BUY	$310.63 - $364.82 $108,099 - $126,957	348 Added 4.51%	8,057 $2.77 Million
Q1 2023 Apr 04, 2023	BUY	$310.63 - $364.82 $71,444 - $83,908	230 Added 2.94%	8,057 $2.77 Million
Q4 2022 Oct 24, 2023	BUY	$321.55 - $374.67 $45,981 - $53,577	143 Added 1.86%	7,827 $2.86 Million
Q3 2022 Oct 03, 2022	SELL	$296.48 - $337.87 $1,482 - $1,689	-5 Reduced 0.06%	7,827 $2.53 Million
Q2 2022 Jul 06, 2022	SELL	$278.73 - $327.27 $27,873 - $32,727	-100 Reduced 1.26%	7,832 $2.54 Million
Q1 2022 Apr 08, 2022	SELL	$234.69 - $291.66 $5,867 - $7,291	-25 Reduced 0.31%	7,932 $2.27 Million
Q4 2021 Jan 11, 2022	SELL	$224.85 - $279.04 $112,425 - $139,520	-500 Reduced 5.91%	7,957 $2.2 Million
Q1 2021 Apr 09, 2021	SELL	$164.32 - $212.72 $4,108 - $5,318	-25 Reduced 0.29%	8,457 $1.58 Million
Q4 2020 Jan 20, 2021	BUY	$130.46 - $172.63 $130,460 - $172,630	1,000 Added 13.37%	8,482 $1.43 Million
Q3 2020 Oct 21, 2020	BUY	$146.22 - $169.13 $288,784 - $334,031	1,975 Added 35.86%	7,482 $1.11 Million
Q1 2020 Apr 28, 2020	SELL	$119.05 - $147.35 $18,690 - $23,133	-157 Reduced 2.77%	5,507 $764,000
Q3 2019 Oct 03, 2019	SELL	$106.79 - $116.16 $40,046 - $43,560	-375 Reduced 6.21%	5,664 $633,000
Q4 2018 Jan 10, 2019	SELL	$105.9 - $118.64 $15,885 - $17,796	-150 Reduced 2.42%	6,039 $699,000
Q3 2018 Oct 05, 2018	SELL	$85.86 - $107.31 $8,586 - $10,731	-100 Reduced 1.59%	6,189 $664,000
Q2 2018 Jul 09, 2018	SELL	$75.7 - $86.88 $908 - $1,042	-12 Reduced 0.19%	6,289 $537,000
Q1 2018 Apr 06, 2018	BUY	$74.21 - $87.6 $7,420 - $8,760	100 Added 1.61%	6,301 $488,000
Q4 2017 Jan 04, 2018	SELL	$81.94 - $87.89 $8,194 - $8,789	-100 Reduced 1.59%	6,201 $524,000
Q3 2017 Oct 18, 2017	BUY	$77.07 - $85.54 $485,618 - $538,987	6,301	6,301 $539,000

Others Institutions Holding LLY

# of Institutions

3,869

Shares Held

751M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $847B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.

Account

Lynch & Associates Eli Lilly & CO Transaction History